Abstract: 9-Chloro-2,4-(un)substituted acridines (1) on condensation with sulpha-diazine, sulphathiazole, and sulphaacetamide gave condensation products 3a-h. 3-Aryl-4-phenyl-2-imino-4-thiazolines (4) on condensation with 9-chloro-2,4-(un)substituted acridines (1) gave condensation products 5a-5o. Both 3a-3h and 5a-5o were puri ed by crystallization or by chromatography. Structures assigned to 3a-3h and 5a-5o are supported by correct spectral data. Antiin®ammatory and analgesic activity screening of 3a, 3e, 3f and 5a-5c, 5e, 5g, 5i, 5m, 5n were carried out using carrageenin induced paw oedema and phenyl quinone writhing assay. Some of the compounds exhibited interesting antiin®ammatory or analgesic activities.
Introduction
Acridine derivatives exhibit fungicidal [1] [2] , antiparasitic [3] , antimicrobial [4] [5] , antitumor [6] [7] [8] , antiin°ammatory and analgesic [9] [10] [11] [12] activities. Some of the acridine derivatives (viz. mepacrine, azacrine, pro°avine, and aminacrine) do also possess antimalarial and antibacterial activities [13] . Another acridine derivative amsacrine has been quite useful as an antitumor agent clinically [14] [15] . Inspired by the wide range of useful biological activities of these derivatives we continued our search for potential antiin°ammatory [16] [17] [18] [19] and anticancer [20] [21] [22] agents and have synthesized a number of acridine derivatives and screened them for antiin°ammatory, analgesic and kinase inhibition activities, results of which are reported in this paper.
Results and Discussion
Sulphadiazine, sulphathiazole and sulphaacetamide were of Aldrich or Sigma make. 9-Chloro-2,4-(un)substituted acridines were synthesized as per procedure reported else where [23] [24] . 3-Aryl-4-phenyl-2-imino-4-thiazolines were prepared by the condensation of phenacyl thiocyanate with amine hydrochlorides as reported in literature [25] .
Solutions of equimolar quantities of 9-chloro-2,4-(un)substituted acridines (1; Figure 1) and sulfa-drugs (2; Figure 1 ) dissolved separately in minimum amounts of methanol were mixed and allowed to stand at room temperature (1-10 days). Solvent was then removed under reduced pressure. The residue left behind was treated with 10% sodium carbonate solution to get crude product, which was puri¯ed by crystallization or column chromatography over silica gel to get pure compounds 3a-3h ( Figure 1 ). The structures assigned to compounds 3a-3h are supported by IR, 1 H NMR, and FABMS or HRMS or EIMS spectral data reported in Table 3 . 3-Aryl-4-phenyl-2-imino-4-thiazolines (4; Figure 1 ) were condensed with 9-chloroacridines (1; Figure 1 ) by re°uxing equimolar quantities of 4 & 1 in methanol for 16-32 hrs. Solvent was then removed under reduced pressure and the residue left behind was treated with 10% aqueous sodium carbonate solution to get crude condensed products, which were puri¯ed by column chromatography over silica gel to get pure condensed products 5a-5o (Figure 1) . Structures of all the synthesized compounds i.e. 5a-o are supported by their IR, 1 H NMR, HRMS or EIMS spectral data, reported in Table 3 Antiin°ammatory activity evaluation [26] of compounds 3a, 3e, 3f, 5b , 5e, 5m, and 5n, at 100 mg/Kg p.o , 5a , 5c , 5g , and 5i , at 80, 20, 40, and 40 mg/Kg p.o. respectively was carried out in rats using carrageenin induced paw oedema. Compounds 3e , 3f , 5a , 5c , 5g , and 5i showed 25, 12.5, 38.4, 20.1, 29.6, and 22.8% activity respectively, whereas the others showed no e®ect.
Analgesic [27] activity of compounds 3a , 3e , 3f , 5a, 5b , 5c, 5e , 5g , 5i, 5m and 5n at 100, 100, 100, 80, 100, 20, 100, 40, 40, 100, and 100 mg/Kg p.o. respectively was evaluated by the writhing assay. Compounds 3a, 3e, 3f , 5a, 5b, 5c, 5e, 5g, 5i, 5m and 5n exhibited, 50, 100, 25, 40, 50, 20, 25, 22, 29, 100 and 75% analgesic activity respectively. Compounds 3a , 3e , 3f , 5b , 5e , 5m, and 5n displayed 25, 50, 0.0, 25, 0.0, 75 and 50% analgesic activity at 50 mg/Kg p.o. respectively.
Kinase inhibition activity [28, 29, 30 ] of 3a-3h, 5a, 5b, 5e, 5g, 5m, 5n for CDK-5 , GSK-3 and 5f-5h, 5j-5o for CDK-1, CDK-5 and GSK-3 was determined and IC 50 values were calculated. In all the cases IC 50 values were found to be > 10 ¹M and hence all the compounds were found to be inactive.
The activity data of 3a, 3e, 3f and 5a, 5b, 5c, 5e, 5g, 5i, 5m, 5n suggest that substitution of methyl group at position 4 of acridine (3e & 5m) is bene¯cial for analgesic activity whereas substitution of the {NO 2 group at the para position of the phenyl group linked with nitrogen of the thiazoline ring (5c; R 5 = NO 2 ) is bene¯cial for antiin°ammatory activity.
Conclusions
A number of acridine derivatives i.e. 3a-3h and 5a-5o were synthesized and characterized by spectroscopic means. Compounds 5a, 5c, 5g exhibited good anti-in°ammatory activity, and 3e, 5m exhibited good analgesic activity. These compounds, however, did not show any kinase inhibition activity.
Experimental
Melting points (m.p.) were determined on a JSGW apparatus and are uncorrected. IR spectra were recorded using a Perkin Elmer 1600FT Spectrometer. Only principal sharply de¯ned IR peaks are reported.
1 H NMR spectra were measured on a Bruker WH-300 Spectrometer in a ca. 5-15% (w/v) solution in DMSO-d 6 (TMS as internal standard). The MS spectrometer peak measurements were made by comparison with per°uorotributylamine using an AEIMS-9 double focusing HRMS at a resolving power of 15000. Thin layer chromatography (TLC) was performed on silica gel G for TLC (Merck) and spots were visualized by iodine vapour or by irradiation with ultraviolet light (254 nm). Column chromatography was performed by using Qualigens silica gel for column chromatography (60-120 mesh).
4.1 General Procedure for Synthesis of 3 4.1.1 Condensation of 9-chloroacridine with sulphadiazine 3a
Sulphadiazaine (250 mg; 1.0 mmol) and 9-chloroacridine (214 mg; 1.0 mmol) were dissolved separately in methanol (25 mL for each) by warming. These solutions were cooled at room temperature, mixed and allowed to stand at room temperature for seven days. Solvent was removed under reduced pressure and the solid residue left behind was suspended in 10% sodium carbonate solution (15 mL) and stirred (20 min). It was then ltered, washed with water and air dried to give crude product 3a, which was puri¯ed by column chromatography over silica gel. Elution solvent, yield, m.p. and spectral data for 3a are reported in Table 3 .
Similar procedure was followed to prepare 3b-3h. Solvent of elution, yield, m.p. and spectral data for 3b-3h are reported in Table 3 . 9-Chloroacridine (214 mg; 1 mmol) was dissolved in methanol (50 mL) and to it was added 3-( o-nitrophenyl )-4-phenyl-2-imino-4-thiazoline (297mg; 1 mmol). The reaction contents were heated under re°ux (16 h) and then the solvent was removed under reduced pressure. The solid residue left behind was suspended in 10 mL (10%) aqueous sodium carbonate solution and stirred (20 min). It was then¯ltered, washed with water and air dried to get crude product 5a. This was puri¯ed by column chromatography over silica gel. Elution with ethyl acetate: chloroform (1:4) gave pure product 5a. Yield, m.p. and spectral data for 5a are reported in Table 3 . Similar procedures were used to prepare compounds 5b-5o. Solvent of elution, yield, m.p. and spectral data for 5b-5o are reported in Table 3 .
Antiin°ammatory activity screening
Antiin°ammatory activity screening [26] was carried out using carrageenin induced paw oedema in albino rats obtained from the animal facility of the Central Drug Research Institute, Lucknow, where they were maintained under standard laboratory conditions. Oedema in one of the hind paws was induced by injection of carrageenin solution (0.1 mL of 1%) into planter apponeurosis. The volume of the paw was measured plethysmographically immediately after the injection of the irritant, and again three hours later. The di®erence in volume gave the amount of oedema developed. Percent inhibition of the oedema between the control group and compound treated groups was calculated, and compared with the group receiving a standard drug. Compounds 3e, 3f, 5a, 5c, 5g, 5i at 100, 100, 80, 20, 40, and 40 mg/Kg p.o. respectively inhibited carrageenin induced hind paw oedema by 25, 12.5, 38.4, 20.1, 29.6 and 22.8% respectively, as compared to standard drug ibuprofen which showed 51% activity at 50 mg/Kg p.o.
Analgesic activity evaluation
Analgesia was measured by the writhing assay [27] using Swiss mice (15{20 gm) bred in the animal house of the Central Drug Research Institute, Lucknow, where they were maintained under standard laboratory conditions. Female mice were screened for writhing on day one by injecting intraperitoneally 0.2 cm 3 of aqueous solution of phenylquinone.
They were kept on a°at surface and the number of writhes of each mouse was recorded for 20 minutes. The mice showing signi¯cant writhes (>10) were separated out and used for analgesic assay on the following day. These mice that showed signi¯cant writhing, consisting of 5 in each group, were given orally 100-20 mg/Kg p.o. dose of the test compounds 15 min. prior to phenylquinone challenge. Writhing was again recorded for each mouse in a group and percentage protection was calculated using formula. 2), 15 mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 mM sodium vanadate, 1 mM NaF, 1 mM phenylphosphate, 10 ¹g leupeptin/mL, 10 ¹g aprotinin/mL, 10 ¹g soybean trypsin inhibitor/mL and 100 ¹M benzamidine. Bu® er A: 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 25 mM tris-HCl pH 7.5, 50 ¹g heparin/mL. Bu® er C: homogenization bu®er but 5 mM EGTA, no NaF and no protease inhibitors. Tris-Bu® ered Saline{Tween-20 (TBST): 50 mM tris pH 7.4, 150mM NaCl, 0.1%-Tween-20. Hypotonic Lysis Bu® er (HLB): 50 mM tris-HCl pH 7.4, 120mM NaCl, 10% glycerol, 1% Nonidet-P40, 5mM DTT, 1 mM EGTA, 20 mM NaF, 1 mM orthovanadate, 5 ¹M microcystin, 100 ¹g/mL each of leupeptin, aprotinin and pepstatin.
Kinase preparations and assays
Kinases activities were assayed in Bu®er A or C (unless otherwise stated), at 30 0 C, at ā nal ATP concentration of 15 ¹M. Blank values were subtracted and activities calculated as picomole of phosphate incorporated for a 10 min. incubation. The activities are usually expressed in % of the maximal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate was assessed by autoradiography after SDS-PAGE. GSK-3¯was either puri¯ed from porcine brain or expressed in and puri¯ed from insect Sf9 cells [28] . It was assayed, following a 1/100 dilution in 1 mg BSA/mL 10mM DTT, with 5¹l40¹M GS-1 peptide as a substrate, in bu®er A, in the presence of 15 ¹M [°¡ 32 P] ATP (3,000 Ci/mmol; 1 mCi/mL) in a¯nal volume of 30 ¹L. After 30 min.
incubation at 30 0 C, 25¹L aliquots of supernatant were spotted onto 2.5 x 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the¯lters were washed ve times (for at least 5 min each time) in a solution of 10mL phosphoric acid/liter of water. The wet¯lters were counted in the presence of 1 mL ACS (Amersham) scintillation°uid. CDK1 / cyclin B was extracted in homogenization bu®er from M phase star¯sh (Marthasterias glacialis) oocytes and puri¯ed by a±nity chromatography on P9 CKShs1 sepharose beads, from which it was eluted by free P9 CKShs1 as reported in the literature [29] [30] .
The kinase activity was assayed in bu®er C, with 1 mg histone H1/mL, in the presence of 15 ¹M[°¡ 32 P]-ATP (3,000 Ci/mmol;mCi/mL) in a¯nal volume of 30¹L. After 10 min. incubation at 30 0 C, 25 ¹L aliquots of supernatant were spotted onto P81 phosphocellulose papers and treated as described above. CDK5/p25 was reconstituted by mixing equal amounts of recombinant mammalian CDK5 and p25 expressed in E. coli as GST (Glutathione-S-transferase) fusion proteins and puri¯ed by a±nity chromatography on glutathione-agarose (vectors kindly provided by Dr. J.H. Wang) (p25 is a truncated version of p35 the 35KDa CDK5 activator). Its activity was assayed in bu®er C as described for CDK1/cyclin B.
[11] A.N. Gaidukevich, G.P. [23] C. 
